Home Newsfeeds UBS Maintains Sell on Peloton Interactive, Lowers Price Target to $8

UBS Maintains Sell on Peloton Interactive, Lowers Price Target to $8

UBS analyst Arpine Kocharyan maintains Peloton Interactive (NASDAQ:PTON) with a Sell and lowers the price target from $13 to $8.

byBenzinga Newsdesk

September 2, 2022

1 minute read

UBS analyst Arpine Kocharyan maintains Peloton Interactive (NASDAQ:PTON) with a Sell and lowers the price target from $13 to $8.

Genetic Testing Pioneer Myriad Genetics’ Evolution Draws Analyst Attention Amid New Product(s) Anticipation

By Vandana Singh

December 21, 2:05 PM

Piper Sandler initiated coverage on Myriad Genetics Inc (NASDAQ: MYGN), noting that many investors know the company as one of the earliest pioneers of genetic testing.

MYGN

BeyondSpring Presents Data With Plinabulin For The Prevention Of Docetaxel-Induced Neutropenia In Patients With Non-Small Cell Lung Cancer And Breast Cancer At Three Medical Conferences

By Benzinga Newsdesk

December 13, 9:08 AM

Additional analyses of non-small cell lung cancer (NSCLC) studies support the efficacy of plinabulin monotherapy in reducing the mean duration of severe neutropenia (DSN) for patients receiving docetaxel In an

BYSI

Informatica Sees Q3 Revenue $395M-$405M Vs $403.28M Est.; FY23 Revenue $1.57B-$1.59B Vs $1.58B Est.

By Happy Mohamed

August 2, 4:14 PM

Third Quarter 2023 Ending September 30, 2023: GAAP Total Revenues are expected to be in the range of $395 million to $405 million, representing approximately 8% year-over-year growth at

INFA

Relmada Therapeutics To Present New Preclinical Data On Its Psilocybin Program At AASLD The Liver Meeting 2023

By Benzinga Newsdesk

October 11, 8:41 AM

Low-dose psilocybin generated statistically significant reductions in liver fat content, plasma glucose levels and body weight gain in a mice model with high-fat-high-fructose diet (HFHFD)-induced metabolic

RLMD

UBS Maintains Sell on Peloton Interactive, Lowers Price Target to $8

Related Posts

Genetic Testing Pioneer Myriad Genetics’ Evolution Draws Analyst Attention Amid New Product(s) Anticipation

BeyondSpring Presents Data With Plinabulin For The Prevention Of Docetaxel-Induced Neutropenia In Patients With Non-Small Cell Lung Cancer And Breast Cancer At Three Medical Conferences

Informatica Sees Q3 Revenue $395M-$405M Vs $403.28M Est.; FY23 Revenue $1.57B-$1.59B Vs $1.58B Est.

Relmada Therapeutics To Present New Preclinical Data On Its Psilocybin Program At AASLD The Liver Meeting 2023